Aicuris Anti-Infective Cures AG is preparing to file for U.S. FDA approval after reporting positive phase III results for lead antiviral pritelivir in the healing of refractory herpes simplex virus lesions in immunocompromised patients.
Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders.
Success by nearly all measures with Praxis Precision Medicines Inc.’s essential tremor phase III candidate, ulixacaltamide, drove the company’s stock up significantly and provided solid data for an NDA filing planned for early 2026.
At the 2025 European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam this week, researchers presented new findings on the role of endocannabinoids in stress, addiction … and the integrity of the blood-brain-barrier.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Abbvie, Akamis, Blacksmith, Cingulate, Corcept, Denali, GSK, Johnson & Johnson, Legend, Krystal, Rocket.
Biopharma happenings, including deals and partnerships, and other news in brief: Boehringer Ingelheim, Cytomed, Frontier, Johnson & Johnson, Nabla, Novo Nordisk, Quantro, Sumitomo, Takeda, TC.
RSS
